Novo Nordisk A/S (NVO) Q2 2013 Earnings Results

Novo-Nordisk A S ADR Reports Q2 2013 Earnings — Stock Reaction Not Available

This earnings report shows that Novo-Nordisk is maintaining strong earnings per share, particularly in its diabetes care segment. However, the lack of revenue data and guidance leaves investors with limited insight into future performance. The stock reaction is not available, making it difficult to gauge market sentiment following the report.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.23	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed cautious optimism about the company's performance, particularly in the diabetes segment. They acknowledged market challenges but emphasized their commitment to innovation and growth.

Management highlighted ongoing strength in their diabetes care segment.

They noted challenges in the broader market but remain focused on innovation.

Future growth is expected to come from new product launches.

Novo-Nordisk A S ADR Reports Q2 2013 Earnings — Stock Reaction Not Available

Key numbers

Management commentary

Novo Nordisk A/S

More earnings this week

Novo-Nordisk A S ADR Reports Q2 2013 Earnings — Stock Reaction Not Available

Key numbers

Management commentary